Literature DB >> 26416546

Cell-specific abnormalities of glutamate transporters in schizophrenia: sick astrocytes and compensating relay neurons?

R E McCullumsmith1, S M O'Donovan1, J B Drummond2, F S Benesh2, M Simmons2, R Roberts2, T Lauriat3, V Haroutunian4,5, J H Meador-Woodruff2.   

Abstract

Excitatory amino-acid transporters (EAATs) bind and transport glutamate, limiting spillover from synapses due to their dense perisynaptic expression primarily on astroglia. Converging evidence suggests that abnormalities in the astroglial glutamate transporter localization and function may underlie a disease mechanism with pathological glutamate spillover as well as alterations in the kinetics of perisynaptic glutamate buffering and uptake contributing to dysfunction of thalamo-cortical circuits in schizophrenia. We explored this hypothesis by performing cell- and region-level studies of EAAT1 and EAAT2 expression in the mediodorsal nucleus of the thalamus in an elderly cohort of subjects with schizophrenia. We found decreased protein expression for the typically astroglial-localized glutamate transporters in the mediodorsal and ventral tier nuclei. We next used laser-capture microdissection and quantitative polymerase chain reaction to assess cell-level expression of the transporters and their splice variants. In the mediodorsal nucleus, we found lower expression of transporter transcripts in a population of cells enriched for astrocytes, and higher expression of transporter transcripts in a population of cells enriched for relay neurons. We confirmed expression of transporter protein in neurons in schizophrenia using dual-label immunofluorescence. Finally, the pattern of transporter mRNA and protein expression in rodents treated for 9 months with antipsychotic medication suggests that our findings are not due to the effects of antipsychotic treatment. We found a compensatory increase in transporter expression in neurons that might be secondary to a loss of transporter expression in astrocytes. These changes suggest a profound abnormality in astrocyte functions that support, nourish and maintain neuronal fidelity and synaptic activity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26416546     DOI: 10.1038/mp.2015.148

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  74 in total

1.  Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia.

Authors:  L V Kristiansen; B Bakir; V Haroutunian; J H Meador-Woodruff
Journal:  Schizophr Res       Date:  2010-03-29       Impact factor: 4.939

2.  Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia.

Authors:  Dan Shan; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Neuroreport       Date:  2012-03-07       Impact factor: 1.837

Review 3.  Glial cells in amyotrophic lateral sclerosis.

Authors:  T Philips; J D Rothstein
Journal:  Exp Neurol       Date:  2014-05-22       Impact factor: 5.330

4.  Evidence for schizophrenia as a disorder of neuroplasticity.

Authors:  Robert E McCullumsmith
Journal:  Am J Psychiatry       Date:  2015-04       Impact factor: 18.112

5.  Hypoxic preconditioning in neonatal rat brain involves regulation of excitatory amino acid transporter 2 and estrogen receptor alpha.

Authors:  Helena Cimarosti; Nicole M Jones; Ross D O'Shea; David V Pow; Christianne Salbego; Philip M Beart
Journal:  Neurosci Lett       Date:  2005-09-02       Impact factor: 3.046

6.  Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate.

Authors:  J D Rothstein; M Dykes-Hoberg; C A Pardo; L A Bristol; L Jin; R W Kuncl; Y Kanai; M A Hediger; Y Wang; J P Schielke; D F Welty
Journal:  Neuron       Date:  1996-03       Impact factor: 17.173

7.  Displacing hexokinase from mitochondrial voltage-dependent anion channel impairs GLT-1-mediated glutamate uptake but does not disrupt interactions between GLT-1 and mitochondrial proteins.

Authors:  Joshua G Jackson; John C O'Donnell; Elizabeth Krizman; Michael B Robinson
Journal:  J Neurosci Res       Date:  2014-12-26       Impact factor: 4.164

8.  Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia.

Authors:  Dan Shan; Elizabeth K Lucas; Jana B Drummond; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2013-01-26       Impact factor: 4.939

9.  Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat.

Authors:  Grant S Goodrich; Anatoli Y Kabakov; Mustafa Q Hameed; Sameer C Dhamne; Paul A Rosenberg; Alexander Rotenberg
Journal:  J Neurotrauma       Date:  2013-07-25       Impact factor: 5.269

10.  Altered expression of the glutamate transporter EAAT2b in neurological disease.

Authors:  Nicholas J Maragakis; Margaret Dykes-Hoberg; Jeffrey D Rothstein
Journal:  Ann Neurol       Date:  2004-04       Impact factor: 10.422

View more
  21 in total

1.  Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders.

Authors:  Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos
Journal:  Antioxid Redox Signal       Date:  2019-02-01       Impact factor: 8.401

2.  Adenosine Kinase Expression in the Frontal Cortex in Schizophrenia.

Authors:  Cassidy L Moody; Adam J Funk; Emily Devine; Ryan C Devore Homan; Detlev Boison; Robert E McCullumsmith; Sinead M O'Donovan
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

3.  Evidence for altered excitatory and inhibitory tone in the post-mortem substantia nigra in schizophrenia.

Authors:  Samuel J Mabry; Lesley A McCollum; Charlene B Farmer; Emma S Bloom; Rosalinda C Roberts
Journal:  World J Biol Psychiatry       Date:  2019-06-04       Impact factor: 4.132

Review 4.  Astrocyte Bioenergetics and Major Psychiatric Disorders.

Authors:  Ivan V Maly; Michael J Morales; Mikhail V Pletnikov
Journal:  Adv Neurobiol       Date:  2021

Review 5.  Astrocytes in Neuropsychiatric Disorders: A Review of Postmortem Evidence.

Authors:  Xiaolu Zhang; Rawan S Alnafisah; Abdul-Rizaq A Hamoud; Rammohan Shukla; Robert E McCullumsmith; Sinead M O'Donovan
Journal:  Adv Neurobiol       Date:  2021

Review 6.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

7.  Cell-subtype-specific changes in adenosine pathways in schizophrenia.

Authors:  Sinead Marie O'Donovan; Courtney Sullivan; Rachael Koene; Emily Devine; Kathryn Hasselfeld; Cassidy Lynn Moody; Robert Erne McCullumsmith
Journal:  Neuropsychopharmacology       Date:  2018-02-26       Impact factor: 7.853

Review 8.  Understanding the genetic liability to schizophrenia through the neuroepigenome.

Authors:  John F Fullard; Tobias B Halene; Claudia Giambartolomei; Vahram Haroutunian; Schahram Akbarian; Panos Roussos
Journal:  Schizophr Res       Date:  2016-01-27       Impact factor: 4.939

Review 9.  Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis.

Authors:  Ronald Kim; Kati L Healey; Marian T Sepulveda-Orengo; Kathryn J Reissner
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-10-06       Impact factor: 5.067

Review 10.  Not Just a Bystander: The Emerging Role of Astrocytes and Research Tools in Studying Cognitive Dysfunctions in Schizophrenia.

Authors:  Chia-Yuan Chang; Da-Zhong Luo; Ju-Chun Pei; Ming-Che Kuo; Yi-Chen Hsieh; Wen-Sung Lai
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.